UB Paderborn / Katalog / Suche / in CDI

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

BMC cancer, 2022-07, Vol.22 (1), p.1-14, Article 820

2022

Volltextzugriff (PDF)

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

BMC cancer, 2019-10, Vol.19 (1), p.990-990, Article 990

2019

Volltextzugriff (PDF)

Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer

BMC medical research methodology, 2018-02, Vol.18 (1), p.23-23, Article 23

2018

Volltextzugriff (PDF)

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

European journal of cancer (1990), 2018-05, Vol.94, p.95-103

2018

Volltextzugriff (PDF)

Reply to the Letter to the Editor ‘The Neonax study’ by M. W. Büchler and J. Neoptolemos

Annals of oncology, 2023-04, Vol.34 (4), p.443-445

2023

Volltextzugriff (PDF)

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Annals of oncology, 2020-02, Vol.31 (2), p.228-235

2020

Volltextzugriff (PDF)

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information

Scientific reports, 2019-09, Vol.9 (1), p.13261-11, Article 13261

2019

Volltextzugriff (PDF)

Metastatic colorectal cancer-Modern treatment strategies and sequences

Innere Medizin (Heidelberg, Germany), 2023-06, Vol.64 (6), p.546

2023

Volltextzugriff (PDF)

EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

Annals of oncology, 2018-04, Vol.29 (4), p.1010-1015

2018

Volltextzugriff (PDF)

A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma

Annals of oncology, 2018-10, Vol.29, p.viii663-viii663

2018

Volltextzugriff (PDF)

Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information

Annals of oncology, 2018-10, Vol.29, p.viii660-viii660

2018

Volltextzugriff (PDF)

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Annals of oncology, 2018-12, Vol.29 (12), p.2393-2395

2018

Volltextzugriff (PDF)

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

ESMO open, 2022-08, Vol.7 (4), p.100552, Article 100552

2022

Volltextzugriff (PDF)

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii139-viii140

2018

Volltextzugriff (PDF)

TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii188-viii189

2018

Volltextzugriff (PDF)

A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii159

2018

Volltextzugriff (PDF)

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

ESMO open, 2022-02, Vol.7 (1), p.100391-100391, Article 100391

2022

Volltextzugriff (PDF)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study

ESMO open, 2022-02, Vol.7 (1), p.100388-100388, Article 100388

2022

Volltextzugriff (PDF)

Colon Polypectomy - And Then?

Zentralblatt fur Chirurgie, 2015-08, Vol.140 (4), p.426

2015

Volltextzugriff (PDF)

Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen

Die Onkologie, 2024-03, Vol.30 (3), p.222-235

2024

Volltextzugriff (PDF)

787PMulticenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

580PQuality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Nal-IRI with 5-fluorouracil an open label, non-comparative, randomized, multicenter phase II study

BMC cancer, 2019-10

2019

Volltextzugriff (PDF)

581PA biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Reply to the Letter to the Editor ‘The Neonax study’ by M. W. Büchler and J. Neoptolemos

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group

Metastatic colorectal cancer-Modern treatment strategies and sequences

EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma

Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO

A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study

Colon Polypectomy - And Then?

Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen

787PMulticenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

580PQuality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

Nal-IRI with 5-fluorouracil an open label, non-comparative, randomized, multicenter phase II study

581PA biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial

Suchergebnisse filtern